← Back to Clinical Trials
Recruiting NCT07518251

NCT07518251 CompaRison of FEmorofemoral Bypass and Left-Heart ByPass Techniques in Open Thoracoabdominal AortIc Aneurysm Repair

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07518251
Status Recruiting
Phase
Sponsor Beijing Anzhen Hospital
Condition Thoracoabdominal Aortic Aneurysm
Study Type INTERVENTIONAL
Enrollment 236 participants
Start Date 2026-04-20
Primary Completion 2028-03-20

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Thoracoabdominal aortic aneurysm repair under fCPBThoracoabdominal aortic aneurysm repair under LHB

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 236 participants in total. It began in 2026-04-20 with a primary completion date of 2028-03-20.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The study is a multicenter, two-arm, open-label, randomized, parallel-controlled trial, which plans to enroll 236 participants diagnosed with TAAA from 4 hospitals in China. All patients receive TAAAR procedure and are randomized to control group (LHB) and experimental group (fCPB) in the ratio of 1:1. After a 1-year follow-up, the validity and safety of the different cardiopulmonary bypass for TAAAR is evaluated via the incidence of major adverse events including surgical mortality, RRT, stroke, and SCI, as well as intraoperative blood product transfusion volume, mechanical ventilation, and early mortality.

Eligibility Criteria

Inclusion Criteria: 1. Computed tomography angiography (CTA) confirmed as ATAAD according to the 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease; 2. Adult patients (≥18 years old); 3. Indications for TAAAR are available and requiring cardiopulmonary bypass; 4. Signed informed consent and availability for follow-up. Exclusion Criteria: 1. History of chronic renal failure, chronic heart failure, Coronary heart disease with established surgical indications, hepatocirrhosis, and hepatic insufficiency; 2. History of severe cerebral infarction (with cerebral infarction sequels); 3. Inflammatory aortic diseases, such as Takayasu arteritis and Behçet's disease, etc; 4. History of infectious aortic diseases; 5. History of malignancy or previous radiotherapy; 6. Pregnant or feeding women, or anyone planning to reproduce during the test period; 7. Participating in any other clinical trial; 8. Having other causes not eligible for operation.

Contact & Investigator

Central Contact

Su-Wei Chen, Doctor

✉ 15524612655@163.com

📞 +86 155 2461 2655

Frequently Asked Questions

Who can join the NCT07518251 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Thoracoabdominal Aortic Aneurysm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07518251 currently recruiting?

Yes, NCT07518251 is actively recruiting participants. Contact the research team at 15524612655@163.com for enrollment information.

Where is the NCT07518251 trial being conducted?

This trial is being conducted at Beijing, China.

Who is sponsoring the NCT07518251 clinical trial?

NCT07518251 is sponsored by Beijing Anzhen Hospital. The trial plans to enroll 236 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology